Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aspirin | 4 | 2018 | 334 | 1.380 |
Why?
|
| Arthroplasty, Replacement, Hip | 3 | 2018 | 111 | 1.380 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2018 | 402 | 1.300 |
Why?
|
| Venous Thromboembolism | 4 | 2018 | 234 | 1.280 |
Why?
|
| Anticoagulants | 6 | 2013 | 559 | 0.960 |
Why?
|
| Dalteparin | 2 | 2013 | 9 | 0.930 |
Why?
|
| Factor Xa Inhibitors | 1 | 2018 | 138 | 0.590 |
Why?
|
| Rivaroxaban | 1 | 2018 | 208 | 0.560 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2018 | 247 | 0.480 |
Why?
|
| Venous Thrombosis | 3 | 2013 | 147 | 0.320 |
Why?
|
| Warfarin | 2 | 2008 | 139 | 0.320 |
Why?
|
| Postoperative Complications | 1 | 2018 | 2235 | 0.290 |
Why?
|
| Catheterization, Central Venous | 1 | 2005 | 95 | 0.230 |
Why?
|
| Postthrombotic Syndrome | 2 | 2013 | 2 | 0.200 |
Why?
|
| Hemorrhage | 2 | 2018 | 623 | 0.200 |
Why?
|
| Double-Blind Method | 4 | 2018 | 1687 | 0.200 |
Why?
|
| Ticlopidine | 1 | 2015 | 61 | 0.130 |
Why?
|
| Stockings, Compression | 1 | 2013 | 5 | 0.120 |
Why?
|
| Intermittent Claudication | 1 | 2015 | 110 | 0.120 |
Why?
|
| Middle Aged | 7 | 2018 | 27627 | 0.110 |
Why?
|
| Ischemia | 1 | 2015 | 374 | 0.100 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 736 | 0.100 |
Why?
|
| Risk Factors | 4 | 2018 | 9003 | 0.090 |
Why?
|
| Male | 8 | 2018 | 57818 | 0.090 |
Why?
|
| Aged | 6 | 2018 | 19661 | 0.090 |
Why?
|
| Patient Selection | 1 | 2013 | 675 | 0.090 |
Why?
|
| Peripheral Arterial Disease | 1 | 2015 | 378 | 0.080 |
Why?
|
| Thrombophilia | 1 | 2008 | 68 | 0.080 |
Why?
|
| Physical Examination | 1 | 2008 | 243 | 0.070 |
Why?
|
| Pulmonary Embolism | 1 | 2008 | 183 | 0.070 |
Why?
|
| Placebos | 1 | 2005 | 202 | 0.060 |
Why?
|
| Catheters, Indwelling | 1 | 2005 | 82 | 0.060 |
Why?
|
| Female | 7 | 2015 | 61588 | 0.060 |
Why?
|
| Adult | 6 | 2015 | 31525 | 0.060 |
Why?
|
| Humans | 8 | 2018 | 119032 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 1802 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2015 | 9346 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2015 | 6562 | 0.050 |
Why?
|
| Radiography | 1 | 2005 | 861 | 0.050 |
Why?
|
| Canada | 2 | 2013 | 340 | 0.050 |
Why?
|
| Recurrence | 2 | 2013 | 975 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 1868 | 0.040 |
Why?
|
| Platelet Function Tests | 1 | 2015 | 25 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 525 | 0.030 |
Why?
|
| Propensity Score | 1 | 2015 | 242 | 0.030 |
Why?
|
| California | 1 | 2015 | 382 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2015 | 151 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 2674 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 842 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 965 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 1125 | 0.030 |
Why?
|
| Neoplasms | 1 | 2005 | 2179 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 1167 | 0.020 |
Why?
|
| Critical Illness | 1 | 2015 | 663 | 0.020 |
Why?
|
| Factor V | 1 | 2008 | 23 | 0.020 |
Why?
|
| Observer Variation | 1 | 2008 | 309 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2008 | 154 | 0.020 |
Why?
|
| Registries | 1 | 2015 | 1810 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 2424 | 0.020 |
Why?
|
| Adolescent | 1 | 2005 | 18483 | 0.020 |
Why?
|
| Time Factors | 1 | 2015 | 6414 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1947 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 2874 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 2275 | 0.010 |
Why?
|
| United States | 1 | 2013 | 12557 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2008 | 6477 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2008 | 4709 | 0.010 |
Why?
|